Capricor Therapeutics (CAPR) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free CAPR Stock Alerts $6.20 0.00 (0.00%) (As of 09:33 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 3:58 AM | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Now Covered by OppenheimerMay 18 at 4:22 PM | msn.comOppenheimer Initiates Coverage of Capricor Therapeutics (CAPR) with Outperform RecommendationMay 17 at 10:22 AM | msn.comNovavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare moversMay 17 at 10:22 AM | msn.comCapricor Therapeutics stock rises, Oppenheimer initiates coverage at OutperformMay 17 at 8:01 AM | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Receives New Coverage from Analysts at OppenheimerOppenheimer started coverage on Capricor Therapeutics in a research report on Friday. They set an "outperform" rating and a $14.00 price objective on the stock.May 17 at 4:24 AM | americanbankingnews.comCapricor Therapeutics Inc (NASDAQ:CAPR) Expected to Earn FY2024 Earnings of ($1.27) Per ShareMay 17 at 2:10 AM | americanbankingnews.comCapricor Therapeutics Inc to Post Q2 2024 Earnings of ($0.34) Per Share, HC Wainwright Forecasts (NASDAQ:CAPR)May 16, 2024 | marketbeat.comCapricor Therapeutics Inc Expected to Earn FY2024 Earnings of ($1.27) Per Share (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of Capricor Therapeutics in a research note issued on Tuesday, May 14th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will earn ($1May 15, 2024 | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for Capricor Therapeutics (NASDAQ:CAPR)May 15, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)May 15, 2024 | americanbankingnews.comLADENBURG THALM/SH SH Boosts Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00May 15, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Downgraded by StockNews.com to "Sell"May 15, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by StockNews.comStockNews.com lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday.May 14, 2024 | msn.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2024 Earnings Call TranscriptMay 14, 2024 | markets.businessinsider.comExpert Ratings For Capricor TherapeuticsMay 14, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $25.00LADENBURG THALM/SH SH boosted their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday.May 14, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday.May 14, 2024 | finance.yahoo.comCapricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | gurufocus.comQ1 2024 Capricor Therapeutics Inc Earnings Call TranscriptMay 13, 2024 | msn.comCAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | msn.comCapricor Therapeutics GAAP EPS of -$0.31 misses by $0.20, revenue of $4.91M misses by $4.79MMay 13, 2024 | globenewswire.comCapricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 12, 2024 | markets.businessinsider.comHere's what to expect from Capricor Therapeutics's earnings reportMay 11, 2024 | americanbankingnews.comCapricor Therapeutics (CAPR) Scheduled to Post Quarterly Earnings on MondayMay 9, 2024 | globenewswire.comCapricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingMay 8, 2024 | globenewswire.comCapricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesMay 7, 2024 | marketbeat.comCapricor Therapeutics (CAPR) Set to Announce Earnings on MondayCapricor Therapeutics (NASDAQ:CAPR) will be releasing earnings after the market closes on Monday, May 13, Zacks reports.May 6, 2024 | globenewswire.comCapricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13April 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical AdvancementsApril 26, 2024 | uk.investing.comCapricor aligns with FDA on drug pathway for muscular dystrophyApril 25, 2024 | markets.businessinsider.comOptimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial PositionApril 25, 2024 | marketbeat.comCapricor Therapeutics' (CAPR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Thursday.April 24, 2024 | markets.businessinsider.comCapricor Announces Positive Type-B Interaction With FDA For CAP-1002 In Treating DMDApril 24, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn SituationApril 24, 2024 | globenewswire.comCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyApril 19, 2024 | markets.businessinsider.comNurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative MedicineApril 10, 2024 | finance.yahoo.comWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should KnowApril 3, 2024 | investing.comCapricor Therapeutics Inc (CAPR)March 21, 2024 | globenewswire.comCapricor Therapeutics to Present at Upcoming Investor ConferencesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial ProspectsMarch 18, 2024 | marketbeat.comFY2024 Earnings Estimate for Capricor Therapeutics Inc Issued By Cantor Fitzgerald (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Capricor Therapeutics in a research report issued on Wednesday, March 13th. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will posMarch 14, 2024 | finance.yahoo.comEarnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech LandscapeMarch 6, 2024 | markets.businessinsider.comCapricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical ProgressMarch 6, 2024 | globenewswire.comCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 3, 2024 | finance.yahoo.comCapricor Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 3, 2024 | seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comQ4 2023 Capricor Therapeutics Inc Earnings CallFebruary 29, 2024 | benzinga.comRecap: Capricor Therapeutics Q4 Earnings Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now CAPR Media Mentions By Week CAPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼-0.160.42▲Average Medical News Sentiment CAPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼332▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRLD News Today SCPH News Today GOSS News Today PRQR News Today RIGL News Today RPTX News Today ALIM News Today CRVO News Today GLSI News Today GALT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
